Article PDF :

Veiw Full Text PDF

Article type :

Original Article

Author :

Rajeev K Saxena, Aziz A Samad, Umar R Khan, Vineet Vinay, Archana C Choure, Sachinkumar V Wankhede, Divyam Saxena

Volume :

7

Issue :

1

Abstract :

Introduction: COVID 19 Pandemic has compelled researchers to revisit available resources for treating these patients. Coronavirus disease (COVID-19) is an infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Lamivudine is the antiviral drug used for treatment of Hepatitis-B, HIV-1 and HIV-2 infection. Aims and objectives: We hypothesise that Lamivudine, may play a role as an effective agent in SARSCoV-2 infection. This is just a pilot study to explore if there is any relation between the two. Materials and Methods: A retrospective study was undertaken through questionnaire-based survey. 100 patients with HBV infection taking Lamivudine treatment were selected. All patients were consecutively enrolled in this study and informed consent was obtained. Results: About 70% of the participants in the Lamivudine group had no fever. Around 59.4% were having fever in the Non-Lamivudine group. The association between presence or absence of fever among family/friends and type of group was assessed. It was found that all the participants in the Non-Lamivudine group (411) and Lamivudine group (100) had fever. Though the percentage of fever was less in the Lamivudine group. The association between home/office in containment zone and type of group was assessed. It was observed that all the participants in both the groups had their home/offices in the containment zone. 43% of the participants in the Lamivudine group had history of domestic travel after 1st march 2020 while 74% had history of domestic travel after 1st march 2020 in the Non-Lamivudine group. 56% of the participants in the Lamivudine group had come in contact with COVID-19 suspected/infected individual as compared to 65.7% in Non-Lamivudine group who had come in contact with COVID-19 suspected/infected individual. 66% of the participants in the Lamivudine group were undergoing preventive medicine for COVID-19 infection & 54.3% of the participants were undergoing preventive medicine for COVID-19 infection in the Non-Lamivudine group. 49% of the participants in the Lamivudine group did not have any other co-morbidities as compared to 63.3% in the Non-Lamivudine group. About 2% of the participants in the Lamivudine group were COVID positive as compared to 48.4% of the participants were COVID positive in the Non-Lamivudine group. There are lower chance of .0217 times of having COVID positive in individuals with Lamivudine medication in comparison of individuals without Lamivudine medication and this association is statistically significant (p< 0>